Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples.
Mireia OlivanMarta GarciaLeticia SuárezMarc GuiuLaura GrosOlga MéndezMarina RigauJaume ReventósMiguel F SeguraInés de TorresJacques PlanasXavier de la CruzRoger R GomisJuan MoroteRuth Rodriguez-BarruecoAnna SantamariaPublished in: Cancers (2021)
About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients' quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells' migratory capacity. Moreover, the PLAG1 , JAKMIP2 , PDGFA , and VTI1b target genes were identified as potential mediators of miR-135b's role in the dissemination to bone. In this study, we provide a genomic signature involved in PCa bone growth, contributing to a better understanding of the mechanisms responsible for this process. In the future, our results could ultimately translate into promising new therapeutic targets for the treatment of lethal PCa.
Keyphrases
- prostate cancer
- bone mineral density
- end stage renal disease
- bone loss
- soft tissue
- bone regeneration
- high throughput
- chronic kidney disease
- signaling pathway
- ejection fraction
- endothelial cells
- radical prostatectomy
- newly diagnosed
- induced apoptosis
- postmenopausal women
- body composition
- stem cells
- prognostic factors
- cell proliferation
- patient reported outcomes
- copy number
- transcription factor
- cell therapy
- epithelial mesenchymal transition
- dna methylation
- induced pluripotent stem cells
- benign prostatic hyperplasia